Download 2015 Breast Publications_FINAL

2015 Cancer Publications
B R E A S T
C A N C E R
Baylor University Medical Center at Dallas
1.
2.
Aapro M, Moebus V, Nitz U, O'Shaughnessy J, Pronzato P, Untch M, Tomita D, Bohac C, Leyland-Jones B.
Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a
meta-analysis. Ann Oncol. 2015;26(4):688-95.
Aapro M, Moebus V, Nitz U, O'Shaughnessy J, Pronzato P, Untch M, Tomita D, Bohac C, Leyland-Jones B.
Reply to letter to the editor 'Primum non nocere' by Templeton and Šeruga. Ann Oncol. 2015;26(10):21989.
3.
Avis NE, Levine BJ, Case LD, Naftalis EZ, Van Zee KJ. Trajectories of Depressive Symptoms Following Breast
4.
Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B,
Cancer Diagnosis. Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1789-95.
Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto
J, Kaneko T, Finkelstein DM, Goss PE; TEACH Investigators. Health related quality of life of women in
TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal
5.
6.
Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 2015;51(6):685-96.
Danhauer SC, Russell G, Case LD, Sohl SJ, Tedeschi RG, Addington EL, Triplett K, Van Zee KJ, Naftalis EZ,
Levine B, Avis NE. Trajectories of Posttraumatic Growth and Associated Characteristics in Women with
Breast Cancer. Ann Behav Med. 2015 Oct;49(5):650-9.
Divers J, O'Shaughnessy J. Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients
With Invasive Breast Cancer. Clin J Oncol Nurs. 2015;19(4):468-74.
B R E A S T
7.
C A N C E R
Early Breast Cancer Trialists' Collaborative Group (EBCTCG; O'Shaughnessy J),
Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von
Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H,
Peto R, Bradley R, Gray R. Adjuvant bisphosphonate treatment in early breast
cancer: meta-analyses of individual patient data from randomised trials. Lancet.
8.
2015;386(10001):1353-61.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG; O'Shaughnessy J ),
Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A,
Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea
D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R. Aromatase
inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of
9.
the randomised trials. Lancet. 2015;386(10001):1341-52.
Grant MD. Cannula-Assisted Flap Elevation (CAFE): a novel technique for
developing flaps during skin-sparing mastectomies. Ann Surg Oncol.
2015;22(2):416-21.
10. Jones C, Tong AW, Mir M, Coyle Y. Lobular carcinoma of the breast with
gastrointestinal metastasis. Proc (Bayl Univ Med Cent). 2015;28(1):50-3.
11. Levin MK, Wang K, Yelensky R, Cao Y, Ramos C, Hoke N, Pippen J Jr, Blum JL, Brooks
B, Palmer G, Palma N, Balasubramanian S, Ross JS, O'Shaughnessy J. Genomic
alterations in DNA repair and chromatin remodeling genes in estrogen receptorpositive metastatic breast cancer patients with exceptional responses to
capecitabine. Cancer Med. 2015;4(8):1289-93.
12. Mason C, Yokubaitis K, Howard E, Shah Z, Wang J. Impact of Henda's law on the
utilization of screening breast magnetic resonance imaging. Proc (Bayl Univ Med
Cent). 2015;28(1):7-9.
13. Millis SZ, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, O'Shaughnessy JA.
Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows
Heterogeneity in TNBC, With Treatment Implications. Clin Breast Cancer.
2015;15(6):473-481.
14. Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobágyi GN, Singletary CN,
Hashmi SS, Arun BK, Litton JK. BRCAPRO 6.0 Model Validation in Male Patients
Presenting for BRCA Testing. Oncologist. 2015;20(6):593-7
B R E A S T
C A N C E R
15. O'Shaughnessy J, Campone M, Brain E, Neven P, Hayes D, Bondarenko I, Griffin TW,
Martin J, De Porre P, Kheoh T, Yu MK, Peng W, Johnston S. Abiraterone acetate,
exemestane or the combination in postmenopausal patients with estrogen
receptor-positive metastatic breast cancer†. Ann Oncol. 2015 Oct 26. pii: mdv487.
[Epub ahead of print]
16. O'Shaughnessy J, McIntyre K, Schwartzberg L, Wilks S, Puhalla S, Berrak E, Song J,
Vahdat L. Impact of prior anthracycline or taxane use on eribulin effectiveness as
first-line treatment for metastatic breast cancer: results from two phase 2,
multicenter, single-arm studies. Springerplus. 2015;4:532.
17. O'Shaughnessy J, Koeppen H, Xiao Y, Lackner MR, Paul D, Stokoe C, Pippen J Jr,
Krekow L, Holmes FA, Vukelja S, Lindquist D, Sedlacek S, Rivera R, Brooks R,
McIntyre K, Brownstein C, Hoersch S, Blum JL, Jones S. Patients with Slowly
Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase
III Adjuvant Trial of Capecitabine. Clin Cancer Res. 2015;21(19):4305-11.
18. Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P,
Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A,
Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J. Etirinotecan pegol
(NKTR-102) versus treatment of physician's choice in women with advanced
breast cancer previously treated with an anthracycline, a taxane, and capecitabine
(BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol.
2015;16(15):1556-68.
19. Roche H, Blum J, Eiermann W, Im YH, Martin M, Mina L, Rugo H, Visco F, Zhang C,
Lokker N, Lounsbury D, Litton J. P1.01A phase 3 study of the oral PARP inhibitor
talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer
(EMBRACA). Ann Oncol. 2015;26 Suppl 2:ii16..
20. Smith JW 2nd, Vukelja S, Hoffman AD, Jones VE, McIntyre K, Berrak E, Song JX,
O'Shaughnessy J. Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin
Combined With Capecitabine for Adjuvant Treatment in Estrogen ReceptorPositive, Early-Stage Breast Cancer. Clin Breast Cancer. 2015 Aug 6. pii: S15268209(15)00167-6. doi: 10.1016/j.clbc.2015.07.007. [Epub ahead of print]
21. Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F,
Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M,
Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE. Long-term hazard of
recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
Breast Cancer Res. 2015;17:56.
22. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo
AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes
DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for
Women With Metastatic Breast Cancer: American Society of Clinical Oncology
Clinical Practice Guideline. J Clin Oncol. 2015;33(24):2695-704.
23. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM,
O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Phase II/III
weekly nab-paclitaxel plus gemcitabine or carboplatin versus
gemcitabine/carboplatin as first-line treatment of patients with metastatic triplenegative breast cancer (the tnAcity study): study protocol for a randomized
controlled trial. Trials. 2015;16(1):575.
B R E A S T
C A N C E R
24. Yardley DA, Bosserman LD, O'Shaughnessy JA, Harwin WN, Morgan SK, Priego VM,
Peacock NW, Bass JD, Burris Iii HA, Hainsworth JD. Paclitaxel, bevacizumab, and
everolimus/placebo as first-line treatment for patients with metastatic HER2-
negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah
Cannon Research Institute. Breast Cancer Res Treat. 2015;154(1):89-97.
25. Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison
MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P,
Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou
CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga
CL. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor
(EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in
Basal-like Breast Cancer. Mol Cell Proteomics. 2015;14(7):1959-76.
For more information about clinical oncology research at Baylor
University Medical Center at Dallas and Baylor Research Institute,
please visit:
BaylorHealth.com/AdvancingMedicine